Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I, single center, randomized, double-blind, placebo controlled, single dose (SD) and multiple dose (MD), dose-escalation clinical trial to evaluate the tolerability and preliminary antiviral activity of therapeutic hepatitis B adenovirus injection (T101) in chronic hepatitis B patients.

Trial Profile

A phase I, single center, randomized, double-blind, placebo controlled, single dose (SD) and multiple dose (MD), dose-escalation clinical trial to evaluate the tolerability and preliminary antiviral activity of therapeutic hepatitis B adenovirus injection (T101) in chronic hepatitis B patients.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs T 101 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions
  • Sponsors Transgene Tasly (Tianjin) BioPharmaceutical
  • Most Recent Events

    • 10 Jul 2018 According to a Transgene media release, Tasly Biopharmaceuticals will control all research, development and commercial rights to T101 in Greater China.
    • 26 Apr 2018 According to a Transgene media release, first patient has been treated in China in this trial.
    • 21 Mar 2018 According to a Transgene media release, full results are expected in 2H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top